Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IM-1021 |
| Synonyms | |
| Therapy Description |
IM-1021 is an antibody-drug conjugate consisting of a ROR1 antibody conjugated to a topoisomerase I inhibitor, which potentially inhibits tumor growth (EORTC-NCI-AACR 2024; Abstract nr 175). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IM-1021 | IM1021|IM 1021 | ROR1 Antibody 8 | IM-1021 is an antibody-drug conjugate consisting of a ROR1 antibody conjugated to a topoisomerase I inhibitor, which potentially inhibits tumor growth (EORTC-NCI-AACR 2024; Abstract nr 175). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06823167 | Phase I | IM-1021 | A Phase 1 Study of IM-1021 in Participants with Advanced Cancer | Recruiting | USA | 0 |